Eagle Pharmaceuticals Achieves Settlement in AAA Arbitration

On July 3, 2024, Skadden secured a settlement on behalf of New Jersey-based pharmaceutical specialty company Eagle Pharmaceuticals, Inc. in connection with a dispute brought by its supplier Curia Global Inc. Curia sought damages in a New York law-governed arbitration administered by the American Arbitration Association alleging that Eagle had failed to pay amounts purportedly owed to Curia under a supply agreement governing the manufacture and supply of vasopressin, a sterile injectable drug used to treat diabetes and COVID-19 patients. The settlement also dismissed a parallel proceeding in New York state court involving a different supply contract between Eagle and Curia.